Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire November 18, 2026

FALLS CHURCH, Va., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“Completing our initial public offering was an important step for Retension, and it provides the capital to complete our Phase 2b clinical trial of RTN-001 and prepare for Phase 3,” said Eric Keller, Chief Executive Officer of Retension Pharmaceuticals. “This year we have also built a leadership team with deep experience advancing cardiovascular and metabolic therapies from clinical development through approval, and formed a Scientific Advisory Board of leading investigators in hypertension, cardiology and nephrology. We remain focused on executing the Phase 2b trial, with initial data expected in the first half of 2027, as we work to bring a new treatment option to patients with uncontrolled and resistant hypertension.”

Recent Corporate Highlights and Upcoming Milestones

Completed initial public offering: In October 2026, Retension completed its upsized initial public offering of 4,312,500 shares of common stock at $12.00 per share, which includes the full exercise of the underwriters’ option to purchase 562,500 additional shares. The offering generated gross proceeds of $51.75 million and net proceeds of approximately $45.1 million. Retension’s common stock began trading on the Nasdaq Capital Market under the ticker symbol “RTSN” on October 9, 2026.

Phase 2b clinical trial of RTN-001 ongoing: The randomized, placebo-controlled, dose-ranging trial is evaluating RTN-001 in approximately 280 patients with uncontrolled hypertension. The study's primary endpoint is the change from baseline in office-seated systolic blood pressure at Week 4 versus placebo. The trial will also inform dose selection for Phase 3. Topline data are expected in the first half of 2027.

Strengthened executive leadership team:

Added biopharma and cardiovascular leadership to the Board of Directors:

Formed Scientific Advisory Board. Bringing together leading investigators in hypertension, cardiology and nephrology:

Third Quarter 2026 Financial Results

About Retension Pharmaceuticals

Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. The Company’s lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension.

About RTN-001

Retension Pharmaceuticals is developing RTN-001, a cardiovascular-targeted, next-generation PDE5 inhibitor designed to directly enhance nitric oxide signaling in central arteries not adequately reached by first-generation PDE5 inhibitors, thereby addressing a core driver of hypertension. RTN-001 has been studied in multiple clinical trials totaling 265 subjects. RTN-001 has a demonstrated efficacy and safety profile in patients and healthy volunteers with clinically meaningful reductions in blood pressure. A Phase 2b trial of RTN-001 in hypertension is ongoing. RTN-001 is being developed under an exclusive world-wide license from Sanofi S.A.

For more information, please see www.retensionpharmaceuticals.com.

Special Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including, but not limited to, statements regarding the Company’s expected cash runway, the use of proceeds from its initial public offering, and the design, progress, timing and results of its Phase 2b clinical trial of RTN-001, and other statements regarding Retension’s future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. These forward-looking statements are based on Retension’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, therefore you should not place undue reliance on these forward-looking statements. The words, including but not limited to, “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “shall,” “should,” “target,” “will,” or “would,” or the negative of these words or other similar terms or expressions are intended to identify these forward-looking statements. Retension’s actual results may differ materially from those expressed in, or implied by, such forward-looking statements due to a number of factors, including but not limited to, risks, uncertainties, assumptions and other factors described in the Company’s final prospectus filed with the U.S. Securities and Exchange Commission (“SEC”) on October 9, 2026 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as well as other documents that may be filed by the Company from time to time with the SEC. Retension undertakes no obligation to update any forward-looking statements after the date of this press release or to conform such statements to actual results or revised expectations, except as required by law.

Contact:

Press and Investor Contact
Alex Schwartz
Chief Financial Officer
investors@retensionpharmaceuticals.com

RETENSION PHARMACEUTICALS, INC.
Condensed Consolidated Statements of Operations (Unaudited)
 
  For the Three Months Ended For the Nine Months Ended
  September 30, September 30,
  2026 2025 2026 2025
Operating Expenses        
Research & development $5,016,602  $1,365,256  $11,219,240  $2,542,254 
General and administrative  990,759   299,574   2,574,495   1,231,791 
Total Operating Expenses  6,007,361   1,664,830   13,793,735   3,774,045 
Loss from Operations  (6,007,361)  (1,664,830)  (13,793,735)  (3,774,045)
Other Income (Expense)            
Exchange loss  —   —   (856)  — 
Interest income  89,277   189,016   351,457   412,558 
Total Other Income  89,277   189,016   350,601   412,558 
Net Loss $(5,918,084) $(1,475,814) $(13,443,134) $(3,361,487)
Net loss per share – Basic and diluted $(7.33) $(1.83) $(16.65) $(4.17)
Weighted-average common shares outstanding -Basic and diluted  807,894   805,154   807,287   805,154 


Condensed Consolidated Balance Sheets
 
    December 31,
  September 30, 2026 2025
  (unaudited) (As Restated)
Assets    
Current Assets    
Cash and cash equivalents $9,190,083  $18,901,024 
Prepaid expenses and other current assets  2,470,521   2,346,077 
Deferred offering costs  2,487,892   198,060 
Total Current Assets  14,148,496   21,445,161 
Total Assets  14,148,496   21,445,161 
Liabilities, Preferred Stock and Stockholders’ Deficit      
Current Liabilities      
Accounts payable  3,886,011   775,859 
Accrued expenses  2,772,818   136,307 
Total Current Liabilities  6,658,829   912,166 
Total Liabilities  6,658,829   912,166 
Commitments and Contingencies      
Convertible Preferred Stock  28,153,769   28,315,918 
Stockholders’ Deficit      
Common stock  81   81 
Additional paid-in-capital  1,094,140   532,185 
Accumulated deficit  (21,758,323)  (8,315,189)
Total Stockholders’ Deficit  (20,664,102)  (7,782,923)
Total Liabilities, Preferred Stock and Stockholders’ Deficit $14,148,496  $21,445,161